HRP20020652A2 - Use of il-18 inhibitors - Google Patents

Info

Publication number

HRP20020652A2

HRP20020652A2 HRP20020652A HRP20020652A2 HR P20020652 A2 HRP20020652 A2 HR P20020652A2 HR P20020652 A HRP20020652 A HR P20020652A HR P20020652 A2 HRP20020652 A2 HR P20020652A2

Authority

HR

Croatia

Prior art keywords

inhibitor

use according

disease

production

treatment

Prior art date

2000-02-21

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title claims abstract description 120
• 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 308
• 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 307
• 238000011282 treatment Methods 0.000 claims abstract description 82
• 206010003246 arthritis Diseases 0.000 claims abstract description 59
• 206010067125 Liver injury Diseases 0.000 claims abstract description 53
• 239000003814 drug Substances 0.000 claims abstract description 47
• 230000002265 prevention Effects 0.000 claims abstract description 44
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 34
• 208000011231 Crohn disease Diseases 0.000 claims abstract description 31
• 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 20
• 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 19
• 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 19
• 102000044166 interleukin-18 binding protein Human genes 0.000 claims description 195
• 108010070145 interleukin-18 binding protein Proteins 0.000 claims description 195
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 97
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 76
• 201000010099 disease Diseases 0.000 claims description 73
• 238000004519 manufacturing process Methods 0.000 claims description 63
• 230000000694 effects Effects 0.000 claims description 53
• 108090000623 proteins and genes Proteins 0.000 claims description 52
• 231100000234 hepatic damage Toxicity 0.000 claims description 45
• 230000008818 liver damage Effects 0.000 claims description 45
• 239000005557 antagonist Substances 0.000 claims description 43
• 102000004169 proteins and genes Human genes 0.000 claims description 42
• 229940079593 drug Drugs 0.000 claims description 36
• 102100035904 Caspase-1 Human genes 0.000 claims description 29
• 108090000426 Caspase-1 Proteins 0.000 claims description 29
• 230000002757 inflammatory effect Effects 0.000 claims description 29
• 238000000034 method Methods 0.000 claims description 29
• 230000037396 body weight Effects 0.000 claims description 27
• 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 24
• 208000002353 alcoholic hepatitis Diseases 0.000 claims description 24
• 108090000467 Interferon-beta Proteins 0.000 claims description 22
• 102000014150 Interferons Human genes 0.000 claims description 22
• 108010050904 Interferons Proteins 0.000 claims description 22
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 18
• 102000001708 Protein Isoforms Human genes 0.000 claims description 18
• 108010029485 Protein Isoforms Proteins 0.000 claims description 18
• 229940079322 interferon Drugs 0.000 claims description 18
• 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 17
• 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 17
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 16
• 102000037865 fusion proteins Human genes 0.000 claims description 16
• 108020001507 fusion proteins Proteins 0.000 claims description 16
• 208000006454 hepatitis Diseases 0.000 claims description 16
• 239000000203 mixture Substances 0.000 claims description 15
• 231100000283 hepatitis Toxicity 0.000 claims description 12
• 239000013598 vector Substances 0.000 claims description 12
• 108060003951 Immunoglobulin Proteins 0.000 claims description 11
• 102000018358 immunoglobulin Human genes 0.000 claims description 11
• 102000003996 Interferon-beta Human genes 0.000 claims description 10
• 102000004557 Interleukin-18 Receptors Human genes 0.000 claims description 10
• 108010017537 Interleukin-18 Receptors Proteins 0.000 claims description 10
• 229960001388 interferon-beta Drugs 0.000 claims description 10
• 229940111134 coxibs Drugs 0.000 claims description 9
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 9
• 239000013604 expression vector Substances 0.000 claims description 9
• 229940124638 COX inhibitor Drugs 0.000 claims description 7
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 claims description 7
• 230000001684 chronic effect Effects 0.000 claims description 7
• 230000002401 inhibitory effect Effects 0.000 claims description 7
• 230000019491 signal transduction Effects 0.000 claims description 7
• 206010019799 Hepatitis viral Diseases 0.000 claims description 6
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims description 6
• 230000001154 acute effect Effects 0.000 claims description 6
• 102000043959 human IL18 Human genes 0.000 claims description 6
• 230000001939 inductive effect Effects 0.000 claims description 6
• -1 muteins Proteins 0.000 claims description 6
• 201000001862 viral hepatitis Diseases 0.000 claims description 6
• 108091026890 Coding region Proteins 0.000 claims description 5
• 101500028161 Homo sapiens Tumor necrosis factor-binding protein 1 Proteins 0.000 claims description 5
• 102400000089 Tumor necrosis factor-binding protein 1 Human genes 0.000 claims description 5
• 230000003187 abdominal effect Effects 0.000 claims description 5
• 230000002708 enhancing effect Effects 0.000 claims description 5
• 238000001415 gene therapy Methods 0.000 claims description 5
• PFBLRDXPNUJYJM-UHFFFAOYSA-N tert-butyl 2-methylpropaneperoxoate Chemical group CC(C)C(=O)OOC(C)(C)C PFBLRDXPNUJYJM-UHFFFAOYSA-N 0.000 claims description 5
• 101500028163 Homo sapiens Tumor necrosis factor-binding protein 2 Proteins 0.000 claims description 4
• 102400000091 Tumor necrosis factor-binding protein 2 Human genes 0.000 claims description 4
• 229940047124 interferons Drugs 0.000 claims description 4
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
• 102000003390 tumor necrosis factor Human genes 0.000 claims 6
• 229940126601 medicinal product Drugs 0.000 claims 4
• 206010007710 Cartilage injury Diseases 0.000 claims 1
• 238000002360 preparation method Methods 0.000 abstract description 6
• 231100000753 hepatic injury Toxicity 0.000 abstract description 4
• 241000699670 Mus sp. Species 0.000 description 120
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 91
• 210000004027 cell Anatomy 0.000 description 90
• 230000014509 gene expression Effects 0.000 description 59
• 108010074328 Interferon-gamma Proteins 0.000 description 49
• 239000002158 endotoxin Substances 0.000 description 49
• 230000001965 increasing effect Effects 0.000 description 47
• 102100037850 Interferon gamma Human genes 0.000 description 46
• 210000004185 liver Anatomy 0.000 description 45
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
• 210000002966 serum Anatomy 0.000 description 43
• 229920006008 lipopolysaccharide Polymers 0.000 description 40
• 235000018102 proteins Nutrition 0.000 description 40
• 108020004999 messenger RNA Proteins 0.000 description 39
• 102000004127 Cytokines Human genes 0.000 description 34
• 108090000695 Cytokines Proteins 0.000 description 34
• 206010061218 Inflammation Diseases 0.000 description 34
• 230000004054 inflammatory process Effects 0.000 description 32
• 241000699666 Mus <mouse, genus> Species 0.000 description 29
• 210000001519 tissue Anatomy 0.000 description 25
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 24
• 210000000845 cartilage Anatomy 0.000 description 24
• 102000005962 receptors Human genes 0.000 description 24
• 241001465754 Metazoa Species 0.000 description 23
• 230000027455 binding Effects 0.000 description 23
• 108020003175 receptors Proteins 0.000 description 23
• 230000006378 damage Effects 0.000 description 22
• 238000002347 injection Methods 0.000 description 20
• 239000007924 injection Substances 0.000 description 20
• 102000004889 Interleukin-6 Human genes 0.000 description 19
• 108090001005 Interleukin-6 Proteins 0.000 description 19
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• 210000001072 colon Anatomy 0.000 description 19
• 230000002829 reductive effect Effects 0.000 description 19
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 18
• 150000001413 amino acids Chemical group 0.000 description 18
• 210000002889 endothelial cell Anatomy 0.000 description 18
• 210000001503 joint Anatomy 0.000 description 18
• 241001529936 Murinae Species 0.000 description 17
• 230000000770 proinflammatory effect Effects 0.000 description 17
• 230000003612 virological effect Effects 0.000 description 17
• 238000002965 ELISA Methods 0.000 description 16
• 235000001014 amino acid Nutrition 0.000 description 16
• 238000002474 experimental method Methods 0.000 description 16
• 210000002683 foot Anatomy 0.000 description 16
• 208000019423 liver disease Diseases 0.000 description 16
• 238000010172 mouse model Methods 0.000 description 16
• 239000011780 sodium chloride Substances 0.000 description 16
• 229940024606 amino acid Drugs 0.000 description 15
• 206010009887 colitis Diseases 0.000 description 15
• 210000002540 macrophage Anatomy 0.000 description 15
• 238000001574 biopsy Methods 0.000 description 14
• 238000007912 intraperitoneal administration Methods 0.000 description 14
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
• 108010082126 Alanine transaminase Proteins 0.000 description 13
• 206010016654 Fibrosis Diseases 0.000 description 13
• 230000000968 intestinal effect Effects 0.000 description 13
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 12
• 102000008186 Collagen Human genes 0.000 description 12
• 108010035532 Collagen Proteins 0.000 description 12
• 102100026720 Interferon beta Human genes 0.000 description 12
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 12
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 12
• 230000004913 activation Effects 0.000 description 12
• 229920001436 collagen Polymers 0.000 description 12
• 210000001165 lymph node Anatomy 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• 206010008909 Chronic Hepatitis Diseases 0.000 description 11
• 208000009386 Experimental Arthritis Diseases 0.000 description 11
• 108010065805 Interleukin-12 Proteins 0.000 description 11
• 102000013462 Interleukin-12 Human genes 0.000 description 11
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 11
• 102000004388 Interleukin-4 Human genes 0.000 description 11
• 108090000978 Interleukin-4 Proteins 0.000 description 11
• 241000700159 Rattus Species 0.000 description 11
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 11
• 230000007882 cirrhosis Effects 0.000 description 11
• 230000003628 erosive effect Effects 0.000 description 11
• 238000011160 research Methods 0.000 description 11
• 238000003757 reverse transcription PCR Methods 0.000 description 11
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 11
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
• 108010062580 Concanavalin A Proteins 0.000 description 10
• 210000001744 T-lymphocyte Anatomy 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 208000002672 hepatitis B Diseases 0.000 description 10
• 229940117681 interleukin-12 Drugs 0.000 description 10
• 210000004400 mucous membrane Anatomy 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 230000008961 swelling Effects 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
• 241000186427 Cutibacterium acnes Species 0.000 description 9
• 101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 9
• 241000283973 Oryctolagus cuniculus Species 0.000 description 9
• 210000001612 chondrocyte Anatomy 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 208000023275 Autoimmune disease Diseases 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 8
• 206010019755 Hepatitis chronic active Diseases 0.000 description 8
• 102000015696 Interleukins Human genes 0.000 description 8
• 108010063738 Interleukins Proteins 0.000 description 8
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
• 230000006866 deterioration Effects 0.000 description 8
• 238000002483 medication Methods 0.000 description 8
• 210000005087 mononuclear cell Anatomy 0.000 description 8
• 230000003472 neutralizing effect Effects 0.000 description 8
• 230000003349 osteoarthritic effect Effects 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 210000000952 spleen Anatomy 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• 102000007469 Actins Human genes 0.000 description 7
• 108010085238 Actins Proteins 0.000 description 7
• 206010061818 Disease progression Diseases 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
• 208000025865 Ulcer Diseases 0.000 description 7
• 230000009471 action Effects 0.000 description 7
• 230000002917 arthritic effect Effects 0.000 description 7
• 210000000013 bile duct Anatomy 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 229940098773 bovine serum albumin Drugs 0.000 description 7
• 230000034994 death Effects 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 239000012634 fragment Substances 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 229940047122 interleukins Drugs 0.000 description 7
• 230000004807 localization Effects 0.000 description 7
• 210000004877 mucosa Anatomy 0.000 description 7
• 102000004196 processed proteins & peptides Human genes 0.000 description 7
• 230000001681 protective effect Effects 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 230000036269 ulceration Effects 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 108010002350 Interleukin-2 Proteins 0.000 description 6
• 102000000588 Interleukin-2 Human genes 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• 206010030113 Oedema Diseases 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
• 125000000539 amino acid group Chemical group 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 239000012228 culture supernatant Substances 0.000 description 6
• 230000005750 disease progression Effects 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 230000001665 lethal effect Effects 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 6
• 229960004963 mesalazine Drugs 0.000 description 6
• 201000008482 osteoarthritis Diseases 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 210000004989 spleen cell Anatomy 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• 201000004595 synovitis Diseases 0.000 description 6
• 210000004876 tela submucosa Anatomy 0.000 description 6
• 230000004580 weight loss Effects 0.000 description 6
• 241000486679 Antitype Species 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• 206010012735 Diarrhoea Diseases 0.000 description 5
• 208000005176 Hepatitis C Diseases 0.000 description 5
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
• 210000000447 Th1 cell Anatomy 0.000 description 5
• 108091007433 antigens Proteins 0.000 description 5
• 102000036639 antigens Human genes 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 230000000112 colonic effect Effects 0.000 description 5
• 230000016396 cytokine production Effects 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 230000005847 immunogenicity Effects 0.000 description 5
• 239000003018 immunosuppressive agent Substances 0.000 description 5
• 231100000518 lethal Toxicity 0.000 description 5
• 231100000225 lethality Toxicity 0.000 description 5
• 230000014759 maintenance of location Effects 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 238000006386 neutralization reaction Methods 0.000 description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 230000008092 positive effect Effects 0.000 description 5
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 210000001258 synovial membrane Anatomy 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 210000002700 urine Anatomy 0.000 description 5
• 238000011725 BALB/c mouse Methods 0.000 description 4
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
• 241000283690 Bos taurus Species 0.000 description 4
• 102000019034 Chemokines Human genes 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
• 108010058846 Ovalbumin Proteins 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 238000000540 analysis of variance Methods 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• 230000003013 cytotoxicity Effects 0.000 description 4
• 231100000135 cytotoxicity Toxicity 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 230000004761 fibrosis Effects 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000002649 immunization Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 210000004969 inflammatory cell Anatomy 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 210000001865 kupffer cell Anatomy 0.000 description 4
• 231100000636 lethal dose Toxicity 0.000 description 4
• 210000005228 liver tissue Anatomy 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 230000003041 necroinflammatory effect Effects 0.000 description 4
• 229940092253 ovalbumin Drugs 0.000 description 4
• 230000001717 pathogenic effect Effects 0.000 description 4
• 102000013415 peroxidase activity proteins Human genes 0.000 description 4
• 108040007629 peroxidase activity proteins Proteins 0.000 description 4
• 208000007232 portal hypertension Diseases 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 241000700199 Cavia porcellus Species 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 206010053567 Coagulopathies Diseases 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
• 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 108090000193 Interleukin-1 beta Proteins 0.000 description 3
• 102000003777 Interleukin-1 beta Human genes 0.000 description 3
• 102000003814 Interleukin-10 Human genes 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• 206010024652 Liver abscess Diseases 0.000 description 3
• 102100025136 Macrosialin Human genes 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
• 210000004241 Th2 cell Anatomy 0.000 description 3
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 206010047700 Vomiting Diseases 0.000 description 3
• 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000003367 anti-collagen effect Effects 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 239000010839 body fluid Substances 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000002440 hepatic effect Effects 0.000 description 3
• 210000004408 hybridoma Anatomy 0.000 description 3
• 229940124589 immunosuppressive drug Drugs 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000031037 interleukin-18 production Effects 0.000 description 3
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000018937 joint inflammation Diseases 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 230000003859 lipid peroxidation Effects 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 239000003226 mitogen Substances 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 210000000287 oocyte Anatomy 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000036470 plasma concentration Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 229940104230 thymidine Drugs 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 210000003556 vascular endothelial cell Anatomy 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
• OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000020154 Acnes Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 206010003011 Appendicitis Diseases 0.000 description 2
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 206010056375 Bile duct obstruction Diseases 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
• 102000001902 CC Chemokines Human genes 0.000 description 2
• 108010040471 CC Chemokines Proteins 0.000 description 2
• 108050006947 CXC Chemokine Proteins 0.000 description 2
• 102000019388 CXC chemokine Human genes 0.000 description 2
• 208000006154 Chronic hepatitis C Diseases 0.000 description 2
• 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 206010010317 Congenital absence of bile ducts Diseases 0.000 description 2
• OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
• 208000037487 Endotoxemia Diseases 0.000 description 2
• 101150064015 FAS gene Proteins 0.000 description 2
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
• 206010016717 Fistula Diseases 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 208000027761 Hepatic autoimmune disease Diseases 0.000 description 2
• 206010019851 Hepatotoxicity Diseases 0.000 description 2
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
• 208000004575 Infectious Arthritis Diseases 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
• 101710205006 Interleukin-18-binding protein Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 2
• 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
• 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 102000008108 Osteoprotegerin Human genes 0.000 description 2
• 108010035042 Osteoprotegerin Proteins 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 238000010240 RT-PCR analysis Methods 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 description 2
• 206010054094 Tumour necrosis Diseases 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000026816 acute arthritis Diseases 0.000 description 2
• 231100000439 acute liver injury Toxicity 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000003356 anti-rheumatic effect Effects 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 239000003435 antirheumatic agent Substances 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 108010068380 arginylarginine Proteins 0.000 description 2
• 210000001188 articular cartilage Anatomy 0.000 description 2
• 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
• 210000000941 bile Anatomy 0.000 description 2
• 201000005271 biliary atresia Diseases 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 208000034158 bleeding Diseases 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000008355 cartilage degradation Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 230000035602 clotting Effects 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 235000005687 corn oil Nutrition 0.000 description 2
• 239000002285 corn oil Substances 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 108010004073 cysteinylcysteine Proteins 0.000 description 2
• 102000026898 cytokine binding proteins Human genes 0.000 description 2
• 108091008470 cytokine binding proteins Proteins 0.000 description 2
• 102000003675 cytokine receptors Human genes 0.000 description 2
• 108010057085 cytokine receptors Proteins 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229920003045 dextran sodium sulfate Polymers 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 235000020188 drinking water Nutrition 0.000 description 2
• 239000003651 drinking water Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000002884 effect on inflammation Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
• 229960005542 ethidium bromide Drugs 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 108010052621 fas Receptor Proteins 0.000 description 2
• 102000018823 fas Receptor Human genes 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 230000003890 fistula Effects 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 208000007386 hepatic encephalopathy Diseases 0.000 description 2
• 210000004024 hepatic stellate cell Anatomy 0.000 description 2
• 208000005252 hepatitis A Diseases 0.000 description 2
• 208000010710 hepatitis C virus infection Diseases 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 231100000304 hepatotoxicity Toxicity 0.000 description 2
• 230000007686 hepatotoxicity Effects 0.000 description 2
• 238000007489 histopathology method Methods 0.000 description 2
• 210000003917 human chromosome Anatomy 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000008105 immune reaction Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000002991 immunohistochemical analysis Methods 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 210000003228 intrahepatic bile duct Anatomy 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 108010054155 lysyllysine Proteins 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 108010085203 methionylmethionine Proteins 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 229960005489 paracetamol Drugs 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 238000010827 pathological analysis Methods 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• 201000001223 septic arthritis Diseases 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000007480 spreading Effects 0.000 description 2
• 238000003892 spreading Methods 0.000 description 2
• 210000005222 synovial tissue Anatomy 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 108010045269 tryptophyltryptophan Proteins 0.000 description 2
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
• 102000019506 tumor necrosis factor binding proteins Human genes 0.000 description 2
• 108091016215 tumor necrosis factor binding proteins Proteins 0.000 description 2
• 230000006433 tumor necrosis factor production Effects 0.000 description 2
• 210000000689 upper leg Anatomy 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 239000002699 waste material Substances 0.000 description 2
• HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
• 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 206010056519 Abdominal infection Diseases 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• BNODVYXZAAXSHW-IUCAKERBSA-N Arg-His Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BNODVYXZAAXSHW-IUCAKERBSA-N 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 206010053555 Arthritis bacterial Diseases 0.000 description 1
• HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
• CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 108010035053 B7-1 Antigen Proteins 0.000 description 1
• 102000038504 B7-1 Antigen Human genes 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• 206010061695 Biliary tract infection Diseases 0.000 description 1
• 208000031648 Body Weight Changes Diseases 0.000 description 1
• 206010051728 Bone erosion Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000001327 Chemokine CCL5 Human genes 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 102000000503 Collagen Type II Human genes 0.000 description 1
• 108010041390 Collagen Type II Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
• 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 description 1
• YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 1
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
• CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 241000711557 Hepacivirus Species 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 206010019773 Hepatitis G Diseases 0.000 description 1
• 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
• 206010019837 Hepatocellular injury Diseases 0.000 description 1
• VHOLZZKNEBBHTH-YUMQZZPRSA-N His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 VHOLZZKNEBBHTH-YUMQZZPRSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000002227 Interferon Type I Human genes 0.000 description 1
• 108010014726 Interferon Type I Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
• 101710149731 Interleukin-1 receptor type 2 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000000743 Interleukin-5 Human genes 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 206010023230 Joint stiffness Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 241000588915 Klebsiella aerogenes Species 0.000 description 1
• HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
• 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000001826 Marfan syndrome Diseases 0.000 description 1
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
• HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 1
• 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
• 206010028124 Mucosal ulceration Diseases 0.000 description 1
• 101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 108010079364 N-glycylalanine Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 1
• 101710104794 Nuclear mitotic apparatus protein 1 Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
• 206010031264 Osteonecrosis Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 238000010222 PCR analysis Methods 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 235000019482 Palm oil Nutrition 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 241000588767 Proteus vulgaris Species 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 206010038063 Rectal haemorrhage Diseases 0.000 description 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 239000008049 TAE buffer Substances 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• BVZABQIRMYTKCF-JSGCOSHPSA-N Trp-Met Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(O)=O)=CNC2=C1 BVZABQIRMYTKCF-JSGCOSHPSA-N 0.000 description 1
• 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
• JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000007495 abnormal renal function Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 231100000354 acute hepatitis Toxicity 0.000 description 1
• 231100000570 acute poisoning Toxicity 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 210000004404 adrenal cortex Anatomy 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 108010047495 alanylglycine Proteins 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000001142 anti-diarrhea Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 108010038633 aspartylglutamate Proteins 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 210000003445 biliary tract Anatomy 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 208000015294 blood coagulation disease Diseases 0.000 description 1
• 230000004579 body weight change Effects 0.000 description 1
• 230000000981 bystander Effects 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000001925 catabolic effect Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 208000003167 cholangitis Diseases 0.000 description 1
• 208000002849 chondrocalcinosis Diseases 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 210000004922 colonic epithelial cell Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 229960003950 combination of corticosteroids Drugs 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000008094 contradictory effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 238000003748 differential diagnosis Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 229960004192 diphenoxylate Drugs 0.000 description 1
• HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000007784 diverticulitis Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 230000002888 effect on disease Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229940092559 enterobacter aerogenes Drugs 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 229940023064 escherichia coli Drugs 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 229940047127 fiore Drugs 0.000 description 1
• 235000021323 fish oil Nutrition 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
• 125000003827 glycol group Chemical group 0.000 description 1
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
• YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
• 210000004565 granule cell Anatomy 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000031169 hemorrhagic disease Diseases 0.000 description 1
• 210000003547 hepatic macrophage Anatomy 0.000 description 1
• 201000010284 hepatitis E Diseases 0.000 description 1
• 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
• 231100000784 hepatotoxin Toxicity 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 230000008076 immune mechanism Effects 0.000 description 1
• 230000003832 immune regulation Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 108010093036 interleukin receptors Proteins 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 210000005206 intestinal lamina propria Anatomy 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 230000008411 joint metabolism Effects 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 231100000849 liver cell damage Toxicity 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000007108 local immune response Effects 0.000 description 1
• 229960001571 loperamide Drugs 0.000 description 1
• RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 108010009298 lysylglutamic acid Proteins 0.000 description 1
• 238000010841 mRNA extraction Methods 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 108010068488 methionylphenylalanine Proteins 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 239000002540 palm oil Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000017924 poor diet Nutrition 0.000 description 1
• 235000003784 poor nutrition Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 108010029020 prolylglycine Proteins 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 229940055019 propionibacterium acne Drugs 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940007042 proteus vulgaris Drugs 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 230000001698 pyrogenic effect Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 238000012340 reverse transcriptase PCR Methods 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000012106 screening analysis Methods 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 210000002832 shoulder Anatomy 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 108091007196 stromelysin Proteins 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000936 topical exposure Toxicity 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• 230000005641 tunneling Effects 0.000 description 1
• 108010003137 tyrosyltyrosine Proteins 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
• 235000005282 vitamin D3 Nutrition 0.000 description 1
• 239000011647 vitamin D3 Substances 0.000 description 1
• 229940021056 vitamin d3 Drugs 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1